Summit Therapeutics
SMMT
52 hedge funds and large institutions have $27.4M invested in Summit Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 11 closing their positions.
0.14% less ownership
Funds ownership: 11.37% → 11.23% (-0.14%)
5% less funds holding
Funds holding: 55 → 52 (-3)
9% less capital invested
Capital invested by funds: $30M → $27.4M (-$2.6M)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$391K |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$390K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$325K |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$41.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$582K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$107K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$103K |
| 4 |
BlackRock
New York
|
-$89.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$86K |
SMMT Hedge Fund Activity: Q1 2022 in Review
52 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2022, worth a combined $27.4M — down 8.6% from $30M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SMMT and 9 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 11 added.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $391K. The largest seller was Russell Investments Group, exiting entirely with an estimated $582K sold.
- 52 institutional investors held Summit Therapeutics (SMMT) as of Q1 2022, down from 55 in Q4 2021.
- Funds reported $27.4M of Summit Therapeutics stock for Q1 2022, down 8.6% quarter-over-quarter.
- 9 funds opened new Summit Therapeutics positions in Q1 2022 and 11 closed out, a net change of -2 holders.
- The largest Summit Therapeutics buyer in Q1 2022 was Boothbay Fund Management, an estimated $391K added.
- The largest Summit Therapeutics seller in Q1 2022 was Russell Investments Group, an estimated $582K sold.
Based on aggregated 13F filings for Q1 2022.